Nanjing Kati Medicine and Nanjing Children's Hospital held a
GD2-CART cell therapy clinical research conference on childhood neuroblastoma
On November 19, the GD2-CART cell therapy clinical research on childhood neuroblastoma was held at the Children’s Hospital of Nanjing Medical University (Nanjing Children’s Hospital). The convening of this conference marked the GD2-CART cell therapy for childhood neuroblastoma. The tumor project clinical research started.
GD2-CART is a CART drug developed by Nanjing Kati Medicine that has passed the identification of GD2 and is a Class 1.1 new drug. The director of the Department of Hematology and Oncology of Nanjing Children's Hospital serves as the general PI of this project. The deputy director of the Department of Hematology and Oncology of Nanjing Children's Hospital, assistant director, and other related researchers attended the meeting.
1 Director Fang's opening speech
2 Dr. Wang Enxiu's speech
The concept of clinical research on GD2-CART cell therapy for childhood neuroblastoma was explained, and the strength of the Katy team and the technical characteristics of Katy were introduced.
3 CTO Dr. Wang Chen reports on the results of preclinical research
5 The two parties had a lively discussion on technical issues
The experts had a lively discussion on patient screening, trial protocol and other issues and finally reached a consensus. At the end of the meeting, Director Fang Yongjun made a summary. He said: The content of this meeting is substantial, detailed explanations are in place, and issues are fully discussed. I believe that with the joint cooperation of all parties, this experiment will be completed scientifically and rigorously. Dr. Wang Enxiu, the founder of Katy Medicine, said that the treatment of solid tumors is a very complicated process. We must be firm and persistent, guard against arrogance and rashness, and do a good job of this research in a down-to-earth manner. Finally, it will help children with theoblastoma patients. Come hope.
At this kick-off meeting, Director Fang and others highly recognized the clinical trial program of GD2-CART cell therapy for childhood neuroblastoma, and also supported and encouraged the Katy team.
The meeting ended successfully, and we look forward to further cooperation and exchanges.
